Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Subscribe To Our Newsletter & Stay Updated
